Squibb Company (NYSE:BMY) today announced results from CheckMate
-066, a Phase 3 randomized double blind study, comparing Opdivo ,
an investigational PD-1 immune checkpoint inhibitor, to the chemotherapy
dacarbazine (DTIC) in patients with treatment naïve BRAF wild-type
advanced melanoma (n=418). The study met the primary endpoint of overall
survival (OS) with the median OS not reached for Opdivo vs.
for Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial investment picks